Just curious if anyone noticed that for the first
Post# of 15624
(Total Views: 810)
Posted On: 06/29/2018 11:25:40 PM
Just curious if anyone noticed that for the first time ever the company finally corrected the spelling of Aviv Barzilay to Aviv Barzilai. I'm sure those of you that have been following this company have noted how some people were having a field day, especially at Lie-Hub with the misspelling.
https://backend.otcmarkets.com/otcapi/company...ntent/html
In an email to Yossi Dagan a couple of weeks ago, I wrote in part:
As always I got a very quick reply:
True to his word Aviv Barzilai's name is finally spelled correctly.
Like many of you I didn't realize there were two parts to the Phase 1 study.
In a conversation that I had with Yossi a month earlier he stated the following:
>Phase 1 is the most important phase.
>Speed and progress is dependent on hospital timing.
>There are Two phases
>Blood test, many failed during the screening phase.
>Phase 2 is straightforward and happens in the patient's home
>Phase 2 is quick and should be finished by Q3.
I'm beginning to think that I may have misunderstood the "second part" thinking it was synonymous with Phase 2.
Like many of you I would love it if they picked up the pace, But some of you, that know much more than I do about the challenges of conducting clinical studies, have pointed out that delays are par for the course. At this point as long as there is progress in the right direction, I'm ok with it.
https://backend.otcmarkets.com/otcapi/company...ntent/html
In an email to Yossi Dagan a couple of weeks ago, I wrote in part:
Quote:
In all of the official filings, the Company has been reporting that Dr. Aviv Barzilay, head of the dermatology department is the one that is overseeing the psoriasis cream study. A simple google search will reveal that there is no Dr. Barzilay at Sheba, but there is a Dr. Barzilai. This is a significan error that should be corrected and if not, then at the very least it should be clarified.
Quote:
Please advise on the progress of the psoriasis study and the name mis-spelling of Dr. Aviv Barzilai.
As always I got a very quick reply:
Quote:
Hi,
Aviv Barzilai is a professor that manage The Department of Dermatology at Sheba hospital and the one who is overseeing our study. Maybe you see it as a significant error, but I don’t see a spelling error as significant but thanks for the comment, it will be corrected in our next filing.
The study is still ongoing. As I mentioned earlier we are dependent on the hospital’s resources so hope to be able to announce soon the results, which at this point I still don’t know what they are as we can’t be involved or influence the study, but wait to the end and the final results.
Will update and communicate to the entire market as soon as we have more info to share.
Thanks,
Yossi
True to his word Aviv Barzilai's name is finally spelled correctly.
Quote:
After completion of the second part of this study , the company plans to initiate a phase II clinical study to demonstrate the efficacy of Topical Ointment in treating mild to moderate psoriasis and other inflammatory skin diseases.
Like many of you I didn't realize there were two parts to the Phase 1 study.
In a conversation that I had with Yossi a month earlier he stated the following:
>Phase 1 is the most important phase.
>Speed and progress is dependent on hospital timing.
>There are Two phases
>Blood test, many failed during the screening phase.
>Phase 2 is straightforward and happens in the patient's home
>Phase 2 is quick and should be finished by Q3.
I'm beginning to think that I may have misunderstood the "second part" thinking it was synonymous with Phase 2.
Like many of you I would love it if they picked up the pace, But some of you, that know much more than I do about the challenges of conducting clinical studies, have pointed out that delays are par for the course. At this point as long as there is progress in the right direction, I'm ok with it.
(5)
(0)OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Scroll down for more posts ▼